Skip to main content
Netherlands News in English

Main navigation

  • Top stories
  • Health
  • Crime
  • Politics
  • Business
  • Tech
  • Culture
  • Sports
  • Weird
  • 1-1-2
Image
Ozempic
Ozempic - Credit: marcbruxelle / DepositPhotos - License: DepositPhotos
Health
Ozempic
Wegovy
Saxenda
overdose
weight loss
NZa
NVIC
UMC Utrecht
Liesbeth van Rossum
Edo Aarts
Erasmus MC
Allurion Clinic
Friday, 23 August 2024 - 08:33

Share this article:

Ozempic overdose: More poisonings with weight loss drugs

The number of overdoses with weight loss drugs is rising rapidly in the Netherlands. Last year, there were 41 reports of poisonings with Ozempic, Wegovy, and Saxenda - over four times as many as in 2021. In the first seven months of this year, there were already 32 cases, BNR reports based on figures from UMC Utrecht’s National Poisons Information Center (NVIC).

People who overdose on these GLP1 agonists typically suffer from nausea and vomiting. In exceptional cases, an overdose can also lead to increased sensitivity or an allergy to the drug.

The main cause of the increase in overdoses is the rapidly growing popularity of these slimming agents. So far, the Dutch Healthcare Authority (NZa) has only approved Saxenda for use against obesity, but Wegovy and Ozempic are also on the Dutch market for treating type 2 diabetes. In practice, they’re also used to lose weight. According to the NZa, almost 90,000 Dutch people used Ozempic last year.

Another factor behind the increase in overdoses is more use outside medical supervision. In 2022, the NVIC registered one overdose in which the patient used the drug without a doctor’s prescription. Halfway through this year, there have already been nine reports.

According to Liesbeth van Rossum, an internist and professor of obesity at the Erasmus MC in Rotterdam, the number of overdoses is “surprisingly low,” given how many Netherlands residents use these medicines. She thinks there are many cases that did not make it into the figures. “I can imagine that you would not immediately call a care provider if you bought this on the internet,” she told the broadcaster.

Edo Aarts, a specialist in treating obesity and co-owner of the Allurion Clinic, added that dosage errors are easy to make, especially with GLP1 agonists bought illegally. Ozempic and Wegovy usually come in lancing devices with a fixed dosage, and patients typically start with a daily dosage of a quarter of a milligram that gradually increases to one milligram. “That quarter of a gram is not available in the illegal circuit. As a result, many people start much too high.”

More like this

Image
Side view of an overweight man measuring his stomach
Dutch hospitals issue warning after fake weight-loss drugs cause comas
Image
Ozempic
More poisonings with weight loss drugs last year
Image
Packaging box of Wegovy (semaglutide), an injectable prescription medication, weight-loss drug by pharmaceutical Novo Nordisk, in a pharmacy
Ozempic-cousin Wegovy unlikely to be covered by basic Dutch health insurance
Image
Ozempic
Hundreds of thousands of Dutch use Ozempic to lose weight; Third without prescription
Make NL Times your top Google source

Follow us:

Latest stories

  • Survey: Dutch travelers shift back toward air travel as car and train use decline
  • Dutch Supreme Court rules against automatic refunds for illegal online gambling losses
  • Dutch coronavirus inquiry witnesses targeted by physical and online threats
  • Amsterdam tests GPS device that warns victims when suspects are nearby
  • Small business owners earn less than freelancers as profits fall in the Netherlands

Top stories

  • Dutch State gave Philip Morris over €1 million to subsidize carbon improvements
  • Hundreds of serious crime convicts handed shorter sentences because trials take too long
  • Victim resuscitated on Rotterdam street after shooting; 5 suspects arrested
  • Societal change behind increase in euthanasia; Doctors experience more pressure
  • Dutch housing market cools off: Fewer mortgage applications, higher  interest rates

© 2012-2026, NL Times, All rights reserved.

Footer menu

  • Change Privacy Settings
  • Privacy Policy
  • Contact
  • Partner Content